The DOI matches its Crossref record.
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study
Open accessAbstract
We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20+, B-cell, non-Hodgkin lymphoma (NHL). We now provide long-term follow-up data in responding patients based on International Workshop Response Criteria. Complete (CR), CR unconfirmed (CRu), and partial response (PR) rates were 29%, 22%, and 22%, respectively (overall response rate 73%, 51% in CR/CRu). Mean time to progression (TTP) and duration of response (DR) in responders were 12.6 months and 11.7 months, respectively. At the maximum tolerated dose (0.4 mCi/kg [14.8 MBq/kg]), TTP and DR in complete responders (CR/CRu) were 28.3 and 27.5 months, respectively. Nine patients (24% of responding patients) had a TTP of more than 3 years. Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma. (Blood. 2004;103:4429-4431)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
Cheson, B. D., & Leonard, J. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708875 · Cited by 438
Czuczman, M. S., Weaver, R., Alkuzweny, B., Berlfein, J., & Grillo-López, A. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.020 · Cited by 366
Sharkey, R. M., Karacay, H., Litwin, S., Rossi, E. A., McBride, W. J., Chang, C.-H., & Goldenberg, D. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0037 · Cited by 75
Monoclonal Antibodies: A Prospective and Retrospective View
Sivaccumar, J., Sandomenico, A., Vitagliano, L., & Ruvo, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200219142231 · Cited by 14
Metadata
- Authors
- Gordon, L. I., Molina, A., Witzig, T., Emmanouilides, C., Raubtischek, A., Darif, M., Schilder, R. J., Wiseman, G., & White, C. A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-06-15
- Volume
- 103
- Issue
- 12
- Pages
- 4429-4431
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2077147663
- Cited by
- 189
- References
- 0
- FWCI
- 14.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. https://app.cochat.ai/papers/10.1182/blood-2003-11-3883
- The paper
- Gordon, L. I., Molina, A., Witzig, T., Emmanouilides, C., Raubtischek, A., Darif, M., Schilder, R. J., Wiseman, G., & White, C. A. (2004). Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. https://doi.org/10.1182/blood-2003-11-3883
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
